Modulating inflammatory cell responses to spinal cord injury: All in good time

Journal of Neurotrauma

Volumn 31, Issue 21, 2014, Pages 1753-1766

  Bowes, Amy L ^a   Yip, Ping K ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

immune cells; immunomodulatory drugs; neuroinflammation; neurotrauma; spinal cord injury

Indexed keywords

CYTOKINE; METHYLPREDNISOLONE; MINOCYCLINE; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; ANTIINFLAMMATORY AGENT;

ASTROCYTE; B LYMPHOCYTE; CELL FUNCTION; CYTOKINE RELEASE; DENDRITIC CELL; IMMUNE RESPONSE; IMMUNOMODULATION; INFLAMMATORY CELL; MACROPHAGE; MICROGLIA; MONOCYTE; NERVOUS SYSTEM INFLAMMATION; NEUTROPHIL; REVIEW; SPINAL CORD INJURY; T LYMPHOCYTE; ANIMAL; COMPLICATION; DRUG EFFECTS; HUMAN; IMMUNOLOGY; INFLAMMATION; LYMPHOCYTE; SPINAL CORD; SPINAL CORD INJURIES;

ANIMALS; ANTI-INFLAMMATORY AGENTS; HUMANS; INFLAMMATION; LYMPHOCYTES; MICROGLIA; SPINAL CORD; SPINAL CORD INJURIES;

EID: 84912077561     PISSN: 08977151     EISSN: 15579042     Source Type: Journal    
DOI: 10.1089/neu.2014.3429     Document Type: Review

References (168)

1. van den Berg, M.E., Castellote, J.M., Mahillo-Fernandez, I., and de Pedro-Cuesta, J. (2010). Incidence of spinal cord injury worldwide: a systematic review. Neuroepidemiology 34, 184-192.
2. Kwon, B.K., Tetzlaff, W., Grauer, J.N., Beiner, J., and Vaccaro, A.R. (2004). Pathophysiology and pharmacologic treatment of acute spinal cord injury. Spine 4, 451-464.
3. Rowland, J.W., Hawryluk, G.W., Kwon, B., and Fehlings, M.G. (2008). Current status of acute spinal cord injury pathophysiology and emerging therapies: promise on the horizon. Neurosurg. Focus 25:E2.
4. Wilson, J.R., Forgione, N., and Fehlings, M.G. (2013). Emerging therapies for acute traumatic spinal cord injury. CMAJ an. Med. Assoc. J. 185, 485-492.
5. Shechter, R., and Schwartz, M. (2013). CNS sterile injury: just another wound healing? Trends Mol. Med. 19, 135-143.
6. Tikka, T., Fiebich, B.L., Goldsteins, G., Keinanen, R., and Koistinaho, J. (2001). Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J. Neurosci. 21, 2580-2588.
7. Nikodemova, M., Watters, J.J., Jackson, S.J., Yang, S.K., and Duncan, I.D. (2007). Minocycline down-regulates MHC II expression in microglia and macrophages through inhibition of IRF-1 and protein kinase C (PKC)(alpha/beta II). J. Biol. Chem. 282, 15208-15216.
8. Casha, S., Zygun, D., McGowan, M.D., Bains, I., Yong, V.W., and Hurlbert, R.J. (2012). Results of a phase II placebo-controlled randomized trial of minocycline in acute spinal cord injury. Brain 135, 1224-1236.
9. Hasegawa-Moriyama, M., Ohnou, T., Godai, K., Kurimoto, T., Na-kama, M., and Kanmura, Y. (2012). Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone attenuates postincisional pain by regulating macrophage polarization. Biochem. Biophys. Res. Com-mun. 426, 76-82.
10. Kobayashi, K., Imagama, S., Ohgomori, T., Hirano, K., Uchimura, K., Sakamoto, K., Hirakawa, A., Takeuchi, H., Suzumura, A., Ishi-guro, N., and Kadomatsu, K. (2013). Minocycline selectively inhibits M1 polarization of microglia. Cell Death Dis. 4, e525.
11. Bracken, M.B., Shepard, M.J., Collins, W.F., Holford, T.R., Young, W., Baskin, D.S., Eisenberg, H.M., Flamm, E., Leo-Summers, L., Maroon, J., et al. (1990). A randomized, controlled trial of methyl-prednisolone or naloxone in the treatment of acute spinal-cord injury. N. Engl. J. Med. 322, 1404-1411.
12. Bracken, M.B. (2012). Steroids for acute spinal cord injury. Co-chrane Database Syst. Rev. 1, CD001046.
13. Hausmann, O. (2003). Post-traumatic inflawing spinal cord injury. Spinal Cord 41, 369-378.
14. Trivedi, A., Olivas, A.D., and Noble-Haeusslein, L.J. (2006). Inflammation and spinal cord injury: Iifiltrating leukocytes as determinants of injury and repair processes. Clin. Neurosci. Res. 6, 283-292.
15. Popovich, P.G., and Jones, T.B. (2003). Manipulating neuroin-flammatory reactions in the injured spinal cord: back to basics. Trends Pharmacol. Sci. 24, 13-17.
16. Smith, J.A., Das, A., Ray, S.K., and Banik, N.L. (2012). Role of pro-inflammatory cytokines released from microglia in neurodegenera-tive diseases. Brain Res. Bull. 87, 10-20.
17. David, S., and Kroner, A. (2011). Repertoire of microglial and macrophage responses after spinal cord injury. Nat. Rev. Neurosci. 12, 388-399.
18. Hughes, P.M., Botham, M.S., Frentzel, S., Mir, A., and Perry, V.H. (2002). Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, during acute and chronic inflammation in the rodent CNS. Glia 37, 314-327.
19. Nishiyori, A., Minami, M., Ohtani, Y., Takami, S., Yamamoto, J., Kawaguchi, N., Kume, T., Akaike, A., and Satoh, M. (1998). Localization of fractalkine and CX3CR1 mRNAs in rat brain: does fractalkine play a role in signaling from neuron to microglia? FEBS Lett. 429, 167-172.
20. Wolf, Y., Yona, S., Kim, K.W., and Jung, S. (2013). Microglia, seen from the CX(3)CR1 angle. Front. Cell. Neurosci. 7, 26.
21. Donnelly, D.J., Longbrake, E.E., Shawler, T.M., Kigerl, K.A., Lai, W.M., Tovar, C.A., Ransohoff, R.M., and Popovich, P.G. (2011). Deficient CX3CR1 signaling promotes recovery after mouse spinal cord injury by limiting the recruitment and activation of Ly6C(lo)/iNOS(+) macrophages. J. Neurosci. 31, 9910-9922.
22. Chen, K., Huang, J., Gong, W., Zhang, L., Yu, P., and Wang, J.M. (2006). CD40/CD40L dyad in the inflammatory and immune responses in the central nervous system. Cell. Mol. Immunol. 3, 163-169.
23. Abdel-Haq, N., Hao, H.N., and Lyman, W.D. (1999). Cytokine regulation of CD40 expression in fetal human astrocyte cultures. J. Neuroimmunol. 101, 7-14.
24. Tian, L., Ma, L., Kaarela, T., and Li, Z. (2012). Neuroimmune crosstalk in the central nervous system and its significance for neurological diseases. J. Neuroinflammation 9, 155.
25. Town, T., Nikolic, V., and Tan, J. (2005). The microglial "activation" continuum: from innate to adaptive responses. J. Neuroinflammation 2, 24.
26. Popovich, P.G., Guan, Z., McGaughy, V., Fisher, L., Hickey, W.F., and Basso, D.M. (2002). The neuropathological and behavioral consequences of intraspinal microglial/macrophage activation. J. Neuropathol. Exp. Neurol. 61, 623-633.
27. Bessis, A., Bechade, C., Bernard, D., and Roumier, A. (2007). Mi-croglial control of neuronal death and synaptic properties. Glia 55, 233-238.
28. Butovsky, O., Ziv, Y., Schwartz, A., Landa, G., Talpalar, A.E., Pluchino, S., Martino, G., and Schwartz, M. (2006). Microglia activated by IL-4 or IFN-gamma differentially induce neurogenesis and oligodendrogenesis from adult stem/progenitor cells. Mol. Cell. Neurosci. 31, 149-160.
29. Ponomarev, E.D., Maresz, K., Tan, Y., and Dittel, B.N. (2007). CNS-Derived interleukin-4 is essential for the regulation of autoimmune inflammation and induces a state of alternative activation in micro-glial cells. J. Neurosci. 27, 10714-10721.
30. Kigerl, K.A., Gensel, J.C., Ankeny, D.P., Alexander, J.K., Donnelly, D.J., and Popovich, P.G. (2009). Identification of two distinct mac-rophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord. J. Neurosci. 29, 13435-13444.
31. Hellwig, S., Heinrich, A., and Biber, K. (2013). The brain's best friend: microglial neurotoxicity revisited. Front. Cell. Neurosci. 7, 71.
32. Remington, L.T., Babcock, A.A., Zehntner, S.P., and Owens, T. (2007). Microglial recruitment, activation, and proliferation in response to primary demyelination. Am. J. Pathol. 170, 1713-1724.
33. Nash, B., Thomson, C.E., Linington, C., Arthur, A.T., McClure, J.D., McBride, M.W., and Barnett, S.C. (2011). Functional duality of as-trocytes in myelination. J. Neurosci 31, 13028-13038.
34. Farina, C., Aloisi, F., and Meinl, E. (2007). Astrocytes are active players in cerebral innate immunity. Trends Immunol. 28, 138-145.
35. Bechmann, I., Galea, I., and Perry, V.H. (2007). What is the blood-brain barrier (not)? Trends Immunol 28, 5-11.
36. Rolls, A., Shechter, R., and Schwartz, M. (2009). The bright side of the glial scar in CNS repair. Nat. Rev. Neurosci. 10, 235-241.
37. Sofroniew, M.V. (2009). Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci. 32, 638-647.
38. Pekny, M., and Nilsson, M. (2005). Astrocyte activation and reactive gliosis. Glia 50, 427-434.
39. Faulkner, J.R., Herrmann, J.E., Woo, M.J., Tansey, K.E., Doan, N.B., and Sofroniew, M.V. (2004). Reactive astrocytes protect tissue and preserve function after spinal cord injury. J. Neurosci. 24, 2143-2155.
40. Bush, T.G., Puvanachandra, N., Horner, C.H., Polito, A., Ostenfeld, T., Svendsen, C.N., Mucke, L., Johnson, M.H., and Sofroniew, M.V. (1999). Leukocyte infiltration, neuronal degeneration, and neurite outgrowth after ablation of scar-forming, reactive astrocytes in adult transgenic mice. Neuron 23, 297-308.
41. Shechter, R., Raposo, C., London, A., Sagi, I., and Schwartz, M. (2011). The glial scar-monocyte interplay: a pivotal resolution phase in spinal cord repair. PloS One 6, e27969.
42. Shechter, R., London, A., Varol, C., Raposo, C., Cusimano, M., Yovel, G., Rolls, A., Mack, M., Pluchino, S., Martino, G., Jung, S., and Schwartz, M. (2009). Infiltrating blood-derived macrophages are vital cells playing an anti-inflammatory role in recovery from spinal cord injury in mice. PloS Med. 6, e1000113.
43. Rolls, A., Shechter, R., London, A., Segev, Y., Jacob-Hirsch, J., Amariglio, N., Rechavi, G., and Schwartz, M. (2008). Two faces of chondroitin sulfate proteoglycan in spinal cord repair: a role in mi-croglia/macrophage activation. PloS Med. 5, e171.
44. Meiron, M., Zohar, Y., Anunu, R., Wildbaum, G., and Karin, N. (2008). CXCL12 (SDF-1 alpha) suppresses ongoing experimental autoimmune encephalomyelitis by selecting antigen-specific regulatory T cells. J. Exp. Med. 205, 2643-2655.
45. Soos, J.M., Morrow, J., Ashley, T.A., Szente, B.E., Bikoff, E.K., and Zamvil, S.S. (1998). Astrocytes express elements of the class II en-docytic pathway and process central nervous system autoantigen for presentation to encephalitogenic T cells. J. Immunol. 161, 5959-5966.
46. Rossi, B., Angiari, S., Zenaro, E., Budui, S.L., and Constantin, G. (2011). Vascular inflammation in central nervous system diseases: adhesion receptors controlling leukocyte-endothelial interactions. J. Leukoc. Biol. 89, 539-556.
47. Lewczuk, P., Reiber, H., and Tumani, H. (1998). Intercellular adhesion molecule-1 in cerebrospinal fluid-the evaluation of blood-derived and brain-derived fractions in neurological diseases. J. Neuroimmunol. 87, 156-161.
48. Fleming, J.C., Norenberg, M.D., Ramsay, D.A., Dekaban, G.A., Marcillo, A.E., Saenz, A.D., Pasquale-Styles, M., Dietrich, W.D., and Weaver, L.C. (2006). The cellular inflammatory response in human spinal cords after injury. Brain 129, 3249-3269.
49. Dusart, I., and Schwab, M.E. (1994). Secondary cell-death and the inflammatory reaction after dorsal hemisection of the rat spinal-cord. Eur. J. Neurosci. 6, 712-724.
50. Pearl-Yafe, M., Fabian, I., Halperin, D., Flatau, E., Werber, S., and Shalit, I. (2007). Interferon-gamma and bacterial lipopolysaccharide act synergistically on human neutrophils enhancing interleukin-8, interleukin-1 beta, tumor necrosis factor-alpha, and interleukin-12 p70 secretion and phagocytosis via upregulation of toll-like receptor 4. Shock 27, 226-231.
51. Carlson, S.L., Parrish, M.E., Springer, J.E., Doty, K., and Dossett, L. (1998). Acute inflammatory response in spinal cord following impact injury. Exp. Neurol. 151, 77-88.
52. de Castro, R., Jr., Hughes, M.G., Xu, G.Y., Clifton, C., Calingasan, N.Y., Gelman, B.B., and McAdoo, D.J. (2004). Evidence that infiltrating neutrophils do not release reactive oxygen species in the site of spinal cord injury. Exp. Neurol. 190, 414-424.
53. Holtz, A., Nyström, B., and Gerdin, B. (1989). Spinal-cord injury in rats-inability of nimodipine or anti-neutrophil serum to improve spinal-cord blood-flow or neurologic status. Acta Neurol. Scand. 79, 460-467.
54. Stirling, D.P., Liu, S.H., Kubes, P. and Yong, V.W. (2009). Depletion of Ly6G/Gr-1 leukocytes after spinal cord injury in mice alters wound healing and worsens neurological outcome. J. Neurosci. 29, 753-764.
55. Noble, L.J., Donovan, F., Igarashi, T., Goussev, S., and Werb, Z. (2002). Matrix metalloproteinases limit functional recovery after spinal cord injury by modulation of early vascular events. J. Neu-rosci. 22, 7526-7535.
56. Weiss, S.J. (1989). Tissue destruction by neutrophils. N. Engl. J. Med. 320, 365-376.
57. Taoka, Y., Okajima, K., Murakami, K., Johno, M., and Naruo, M. (1998). Role of neutrophil elastase in compression-induced spinal cord injury in rats. Brain Res. 799, 264-269.
58. Pellegatta, F., Lu, Y., Radaelli, A., Zocchi, M.R., Ferrero, E., Chierchia, S., Gaja, G., and Ferrero, M.E. (1996). Drug-induced in vitro inhibition of neutrophil-endothelial cell adhesion. Br. J. Pharmacol. 118, 471-476.
59. Miller, Y.I., Choi, S.H., Wiesner, P., Fang, L.H., Harkewicz, R., Hartvigsen, K., Boullier, A., Gonen, A., Diehl, C.J., Que, X.C., Montano, E., Shaw, P.X., Tsimikas, S., Binder, C.J., and Witztum, J.L. (2011). Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity. Circ. Res. 108, 235-248.
60. Greenberg, M.E., Sun, M.J., Zhang, R.L., Febbraio, M., Silverstein, R., and Hazen, S.L. (2006). Oxidized phosphatidylserine-CD36 interactions play an essential role in macrophage-dependent phagocytosis of apoptotic cells. J. Exp. Med. 203, 2613-2625.
61. Martinez, F.O., Helming, L., and Gordon, S. (2009). Alternative activation of macrophages: an immunologic functional perspective. Ann. Rev. Immunol. 27, 451-483.
62. Gordon, S., and Taylor, P.R. (2005). Monocyte and macrophage heterogeneity. Nat. Rev. Immunol. 5, 953-964.
63. Sica, A., Schioppa, T., Mantovani, A., and Allavena, P. (2006). Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur. J. Cancer 42, 717-727.
64. Schonberg, D.L., Popovich, P.G., and McTigue, D.M. (2007). Oli-godendrocyte generation is differentially influenced by toll-like receptor (TLR) 2 and TLR4-Mediated intraspinal macrophage activation. J. Neuropathol. Exp. Neurol. 66, 1124-1135.
65. Gensel, J.C., Nakamura, S., Guan, Z., van Rooijen, N., Ankeny, D.P., and Popovich, P.G. (2009). Macrophages promote axon regeneration with concurrent neurotoxicity. J. Neurosci. 29, 3956-3968.
66. Rapalino, O., Lazarov-Spiegler, O., Agranov, E., Velan, G.J., Yoles, E., Fraidakis, M., Solomon, A., Gepstein, R., Katz, A., Belkin, M., Hadani, M., and Schwartz, M. (1998). Implantation of stimulated homologous macrophages results in partial recovery of paraplegic rats. Nat. Med. 4, 814-821.
67. Schwartz, M., Lazarov-Spiegler, O., Rapalino, O., Agranov, I., Ve-lan, G., and Hadani, M. (1999). Potential repair of rat spinal cord injuries using stimulated homologous macrophages. Neurosurgery 44, 1041-1046.
68. Bomstein, Y., Marder, J.B., Vitner, K., Smirnov, I., Lisaey, G., Butovsky, O., Fulga, V., and Yoles, E. (2003). Features of skin-coincubated macrophages that promote recovery from spinal cord injury. J. Neuroimmunol. 142, 10-16.
69. Lammertse, D.P., Jones, L.A., Charlifue, S.B., Kirshblum, S.C., Apple, D.F., Ragnarsson, K.T., Falci, S.P., Heary, R.F., Choudhri, T.F., Jenkins, A.L., Betz, R.R., Poonian, D., Cuthbert, J.P., Jha, A., Snyder, D.A., and Knoller, N. (2012). Autologous incubated macrophage therapy in acute, complete spinal cord injury: results of the phase 2 randomized controlled multicenter trial. Spinal Cord 50, 661-671.
70. Sroga, J.M., Jones, T.B., Kigerl, K.A., McGaughy, V.M., and Po-povich, P.G. (2003). Rats and mice exhibit distinct inflammatory reactions after spinal cord injury. J. Comp. Neurol. 462, 223-240.
71. Greter, M., Heppner, F.L., Lemos, M.P., Odermatt, B.M., Goebels, N., Laufer, T., Noelle, R.J., and Becher, B. (2005). Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat. Med. 11, 328-334.
72. McMahon, E.J., Bailey, S.L., Castenada, C.V., Waldner, H., and Miller, S.D. (2005). Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis. Nat. Med. 11, 335-339.
73. Wang, Y., Wang, K., Chao, R., Li, J., Zhou, L., Ma, J., and Yan, J. (2012). Neuroprotective effect of vaccination with autoantigen-pulsed dendritic cells after spinal cord injury. J. Surg. Res. 176, 281-292.
74. Weir, C.R., Nicolson, K., and Bäckström, B.T. (2002). Experimental autoimmune encephalomyelitis induction in naive mice by dendritic cells presenting a self-peptide. Immunol. Cell Biol. 80, 14-20.
75. Hawiger, D., Inaba, K., Dorsett, Y., Guo, M., Mahnke, K., Rivera, M., Ravetch, J.V., Steinman, R.M., and Nussenzweig, M.C. (2001). Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J. Exp. Med. 194, 769-779.
76. Banchereau, J., and Steinman, R.M. (1998). Dendritic cells and the control of immunity. Nature 392, 245-252.
77. Wang, K., Chao, R., Guo, Q.N., Liu, M.Y., Liang, H.P., Liu, P., and Zhao, J.H. (2013). Expressions of some neurotrophins and neuro-trophic cytokines at site of spinal cord injury in mice after vaccination with dendritic cells pulsed with homogenate proteins. Neuroimmunomodulation 20, 87-98.
78. Mikami, Y., Okano, H., Sakaguchi, M., Nakamura, M., Shimazaki, T., Okano, H.J., Kawakami, Y., Toyama, Y., and Toda, M. (2004). Implantation of dendritic cells in injured adult spinal cord results in activation of endogenous neural stem/progenitor cells leading to de novo neurogenesis and functional recovery. J. Neurosci. Res. 76, 453-465.
79. Jones, T.B., Hart, R.P., and Popovich, P.G. (2005). Molecular control of physiological and pathological T-cell recruitment after mouse spinal cord injury. J. Neurosc. 25, 6576-6583.
80. Popovich, P.G., Stuckman, S., Gienapp, I.E., and Whitacre, C.C. (2001). Alterations in immune cell phenotype and function after experimental spinal cord injury. J. Neurotrauma 18, 957-966.
81. Ankeny, D.P., and Popovich, P.G. (2009). Mechanisms and implications of adaptive immune responses after traumatic spinal cord injury. Neuroscience 158, 1112-1121.
82. Ling, C., Sandor, M., and Fabry, Z. (2003). In situ processing and distribution of intracerebrally injected OVA in the CNS. J. Neu-roimmunol. 141, 90-98.
83. Karman, J., Ling, C., Sandor, M., and Fabry, Z. (2004). Initiation of immune responses in brain is promoted by local dendritic cells. J. Immunol. 173, 2353-2361.
84. Kigerl, K.A., McGaughy, V.M., and Popovich, P.G. (2006). Comparative analysis of lesion development and intraspinal inflammation in four strains of mice following spinal contusion injury. J. Comp. Neurol. 494, 578-594.
85. Karin, N., Mitchell, D.J., Brocke, S., Ling, N., and Steinman, L. (1994). Reversal of experimental autoimmune encephalomyelitis by a soluble peptide variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of interferon gamma and tumor necrosis factor alpha production. J. Exp. Med. 180, 2227-2237.
86. Popovich, P.G., Stokes, B.T., and Whitacre, C.C. (1996). Concept of autoimmunity following spinal cord injury: possible roles for T lymphocytes in the traumatized central nervous system. J. Neurosci. Res. 45, 349-363.
87. Siffrin, V., Brandt, A.U., Radbruch, H., Herz, J., Boldakowa, N., Leuenberger, T., Werr, J., Hahner, A., Schulze-Topphoff, U., Nitsch, R., and Zipp, F. (2009). Differential immune cell dynamics in the CNS cause CD4 T cell compartmentalization. Brain 132, 1247-1258.
88. Hauben, E., Butovsky, O., Nevo, U., Yoles, E., Moalem, G., Agra-nov, E., Mor, F., Leibowitz-Amit, R., Pevsner, E., Akselrod, S., Neeman, M., Cohen, I.R., and Schwartz, M. (2000). Passive or active immunization with myelin basic protein promotes recovery from spinal cord contusion. J. Neurosci. 20, 6421-6430.
89. Moalem, G., Yoles, E., Leibowitz-Amit, R., Muller-Gilor, S., Mor, F., Cohen, I.R., and Schwartz, M. (2000). Autoimmune T cells retard the loss of function in injured rat optic nerves. J. Neuroimmunol. 106, 189-197.
90. Wu, B., Matic, D., Djogo, N., Szpotowicz, E., Schachner, M., and Jakovcevski, I. (2012). Improved regeneration after spinal cord injury in mice lacking functional T-and B-lymphocytes. Exp. Neurol. 237, 274-285.
91. Hoffmann, K.F., Cheever, A.W., and Wynn, T.A. (2000). IL-10 and the dangers of immune polarization: Excessive type 1 and type 2 cytokine responses induce distinct forms of lethal immunopathology in murine schistosomiasis. J. Immunol. 164, 6406-6416.
92. Oldroyd, S.D., Thomas, G.L., Gabbiani, G., and El Nahas, A.M. (1999). Interferon-gamma inhibits experimental renal fibrosis. Kidney Int 56, 2116-2127.
93. Hesse, M., Modolell, M., La Flamme, A.C., Schito, M., Fuentes, J.M., Cheever, A.W., Pearce, E.J., and Wynn, T.A. (2001). Differential regulation of nitric oxide synthase-2 and arginase-1 by type 1/type 2 cytokines in vivo: Granulomatous pathology is shaped by the pattern of L-arginine metabolism. J. Immunol. 167, 6533-6544.
94. Witte, M.B., Barbul, A., Schick, M.A., Vogt, N., and Becker, H.D. (2002). Upregulation of arginase expression in wound-derived fi-broblasts. J. Surg. Res. 105, 35-42.
95. Ankeny, D.P., Lucin, K.M., Sanders, V.M., McGaughy, V.M., and Popovich, P.G. (2006). Spinal cord injury triggers systemic autoim-munity: evidence for chronic B lymphocyte activation and lupus-like autoantibody synthesis. J. Neurochem. 99, 1073-1087.
96. Yip, P.K., and Malaspina, A. (2012). Spinal cord trauma and the molecular point of no return. Mol. Neurodegener. 7, 6.
97. Kwon, B.K., Stammers, A.M., Belanger, L.M., Bernardo, A., Chan, D., Bishop, C.M., Slobogean, G.P., Zhang, H., Umedaly, H., Giffin, M., Street, J., Boyd, M.C., Paquette, S.J., Fisher, C.G., and Dvorak, M.F. (2010). Cerebrospinal fluid inflammatory cytokines and bio-markers of injury severity in acute human spinal cord injury. J. Neurotrauma 27, 669-682.
98. Yang, L., Jones, N.R., Blumbergs, P.C., Van Den Heuvel, C., Moore, E.J., Manavis, J., Sarvestani, G.T., and Ghabriel, M.N. (2005). Severity-dependent expression of pro-inflammatory cyto-kines in traumatic spinal cord injury in the rat. J. Clin. Neurosci. 12, 276284.
99. Gwak, Y.S., Kang, J., Unabia, G.C., and Hulsebosch, C.E. (2012). Spatial and temporal activation of spinal glial cells: Role of gliopathy in central neuropathic pain following spinal cord injury in rats. Exp. Neurol. 234, 362-372.
100. Yong, V.W., Wells, J., Giuliani, F., Casha, S., Power, C., and Metz, L.M. (2004). The promise of minocycline in neurology. Lancet Neurol. 3, 744-751.
101. Kielian, T., Esen, N., Liu, S.L., Phulwani, N.K., Syed, M.M., Phillips, N., Nishina, K., Cheung, A.L., Schwartzman, J.D., and Ruhe, J.J. (2007). Minocycline modulates neuroinflammation independently of its antimicrobial activity in staphylococcus aureus-induced brain abscess. Am. J. Pathol. 171, 1199-1214.
102. Sapadin, A.N., and Fleischmajer, R. (2006). Tetracyclines: Non-antibiotic properties and their clinical implications. J. Am. Acad. Dermatol. 54, 258-265.
103. Zemke, D., and Majid, A. (2004). The potential of minocycline for neuroprotection in human neurologic disease. Clin. Neuropharmacol. 27, 293-298.
104. Defaux, A., Zurich, M.G., Honegger, P., and Monnet-Tschudi, F. (2011). Minocycline promotes remyelination in aggregating rat brain cell cultures after interferon-gamma plus lipopolysaccharide-induced demyelination. Neuroscience 187, 84-92.
105. Garrido-Mesa, N., Zarzuelo, A., and Galvez, J. (2013). Minocycline: far beyond an antibiotic. Br. J. Pharmacol. 169, 337-352.
106. Stirling, D.P., Khodarahmi, K., Liu, J., McPhail, L.T., McBride, C.B., Steeves, J.D., Ramer, M.S. and Tetzlaff, W. (2004). Minocy-cline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury. J. Neurosci. 24, 2182-2190.
107. Wells, J.E., Hurlbert, R.J., Fehlings, M.G., and Yong, V.W. (2003). Neuroprotection by minocycline facilitates significant recovery from spinal cord injury in mice. Brain 126, 1628-1637.
108. Cristiano, L., Bernardo, A., and Ceru, M.P. (2001). Peroxisome proliferator-activated receptors (PPARs) and peroxisomes in rat cortical and cerebellar astrocytes. J. Neurocytol. 30, 671-683.
109. Cullingford, T.E., Bhakoo, K., Peuchen, S., Dolphin, C.T., Patel, R., and Clark, J.B. (1998). Distribution of mRNAs encoding the per-oxisome proliferator-activated receptor alpha, beta and gamma and the retinoid X receptor alpha, beta and gamma rat central nervous system. J. Neurochem. 70, 1366-1375.
110. Luna-Medina, R., Cortes-Canteli, M., Alonso, M., Santos, A., Martinez, A., and Perez-Castillo, A. (2005). Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator-activated receptor gamma activation. J. Biol. Chem. 280, 21453-21462.
111. Luna-Medina, R., Cortes-Canteli, M., Sanchez-Galiano, S., Morales-Garcia, J.A., Martinez, A., Santos, A., and Perez-Castillo, A. (2007). NP031112, a thiadiazolidinone compound, prevents inflammation and neurodegeneration under excitotoxic conditions: Potential therapeutic role in brain disorders. J. Neurosci. 27, 5766-5776.
112. Toyomoto, M., Ohta, M., Okumura, K., Yano, H., Matsumoto, K., Inoue, S., Hayashi, K., and Ikeda, K. (2004). Prostaglandins are powerful inducers of NGF and BDNF production in mouse astrocyte cultures. FEBS Lett. 562, 211-215.
113. Xu, J.H., and Drew, P.D. (2007). Peroxisome proliferator-activated receptor-gamma agonists suppress the production of IL-12 family cytokines by activated glia. J. Immunol. 178, 1904-1913.
114. Kanakasabai, S., Chearwae, W., Walline, C.C., Iams, W., Adams, S.M., and Bright, J.J. (2010). Peroxisome proliferator-activated receptor delta agonists inhibit T helper type 1 (Th1) and Th17 responses in experimental allergic encephalomyelitis. Immunology 130, 572-588.
115. Bernardo, A., Ajmone-Cat, M.A., Levi, G., and Minghetti, L. (2003). 15-deoxy-delta12, 14-prostaglandin J2 regulates the functional state and the survival of microglial cells through multiple molecular mechanisms. J. Neurochem. 87, 742-751.
116. Carta, A.R., Frau, L., Pisanu, A., Wardas, J., Spiga, S., and Carboni, E. (2011). Rosiglitazone decreases peroxisome proliferator receptor-gamma levels in microglia and inhibits tnf-alpha production: new evidences on neuroprotection in a progressive Parkinson's disease model. Neuroscience 194, 250-261.
117. Bernardo, A., Levi, G., and Minghetti, L. (2000). Role of the per-oxisome proliferator-activated receptor-gamma (PPAR-gamma) and its natural ligand 15-deoxy-Delta12, 14-prostaglandin J2 in the regulation of microglial functions. Eur. J. Neurosci. 12, 2215-2223.
118. Li, X., Du, J., Xu, S., Lin, X., and Ling, Z. (2013). Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces secondary damage in experimental spinal cord injury. J. Int. Med. Res. 41, 153-161.
119. Lim, S.N., Huang, W.L., Hall, J.C., Ward, R.E., Priestley, J.V., and Michael-Titus, A.T. (2010). The acute administration of eicosa-pentaenoic acid is neuroprotective after spinal cord compression injury in rats. Prostaglandins Leukot. Essent. Fatty Acids 83, 193-201.
120. Ward, R.E., Huang, W.L., Curran, O.E., Priestley, J.V., and Michael-Titus, A.T. (2010). Docosahexaenoic acid prevents white matter damage after spinal cord injury. J. Neurotrauma 27, 1769-1780.
121. Huang, W.L., King, V.R., Curran, O.E., Dyall, S.C., Ward, R.E., Lal, N., Priestley, J.V., and Michael-Titus, A.T. (2007). A combination of intravenous and dietary docosahexaenoic acid significantly improves outcome after spinal cord injury. Brain 130, 3004-3019.
122. Ebert, S., Weigelt, K., Walczak, Y., Drobnik, W., Mauerer, R., Hume, D.A., Weber, B.H., and Langmann, T. (2009). Docosahex-aenoic acid attenuates microglial activation and delays early retinal degeneration. J. Neurochem. 110, 1863-1875.
123. Paterniti, I., Impellizzeri, D., Di Paola, R., Esposito, E., Gladman, S., Yip, P., Priestley, J.V., Michael-Titus, A.T., and Cuzzocrea, S. (2014). Docosahexaenoic acid attenuates the early inflammatory response following spinal cord injury in mice: in-vivo and in-vitro studies. J. Neuroinflammation 11, 6.
124. Chvatal, S.A., Kim, Y.T., Bratt-Leal, A.M., Lee, H., and Bellam-konda, R.V. (2008). Spatial distribution and acute anti-inflammatory effects of Methylprednisolone after sustained local delivery to the contused spinal cord. Biomaterials 29, 1967-1975.
125. Can, M., Gul, S., Bektas, S., Hanci, V., and Acikgoz, S. (2009). Effects of dexmedetomidine or methylprednisolone on inflammatory responses in spinal cord injury. Acta Anaesthesiol. Scand. 53, 1068-1072.
126. Viscomi, M.T., Florenzano, F., Latini, L., Amantea, D., Bernardi, G., and Molinari, M. (2008). Methylprednisolone treatment delays remote cell death after focal brain lesion. Neuroscience 154, 1267-1282.
127. Sloka, J.S., and Stefanelli, M. (2005). The mechanism of action of methylprednisolone in the treatment of multiple sclerosis. Mult. Scler. 11, 425-432.
128. Leussink, V.I., Jung, S., Merschdorf, U., Toyka, K.V., and Gold, R. (2001). High-dose methylprednisolone therapy in multiple sclerosis induces apoptosis in peripheral blood leukocytes. Arch. Neurol. 58, 91-97.
129. Gayo, A., Mozo, L., Suarez, A., Tunon, T.B., Lahoz, C., and Gutierrez, C. (1998). Glucocorticoids increase IL-10 expression in multiple sclerosis patients with acute relapse. J. Neuroimmunol. 85, 122-130.
130. Ozenci, V., Pashenkov, M., Kouwenhoven, M., Rinaldi, L., Söder-ström, M., and Link, H. (2001). IL-12/IL-12R system in multiple sclerosis. J. Neuroimmunol. 114, 242-252.
131. Gelati, M., Corsini, E., Dufour, A., Massa, G., Giombini, S., Solero, C.L. and Salmaggi, A. (2000). High-dose methylprednisolone reduces cytokine-induced adhesion molecules on human brain endo-thelium. Can. J. Neurol. Sci. 27, 241-244.
132. Elovaara, I., Lalla, M., Spare, E., Lehtimaki, T., and Dastidar, P. (1998). Methylprednisolone reduces adhesion molecules in blood and cerebrospinal fluid in patients with MS. Neurology 51, 1703-1708.
133. Lucin, K.M., Sanders, V.M. and Popovich, P.G. (2009). Stress hormones collaborate to induce lymphocyte apoptosis after high level spinal cord injury. J. Neurochem. 110, 1409-1421.
134. Riegger, T., Conrad, S., Liu, K., Schluesener, H.J., Adibzahdeh, M., and Schwab, J.M. (2007). Spinal cord injury-induced immune depression syndrome (SCI-IDS). Eur. J. Neurosci. 25, 1743-1747.
135. Kliesch, W.F., Cruse, J.M., Lewis, R.E., Bishop, G.R., Brackin, B., and Lampton, J.A. (1996). Restoration of depressed immune function in spinal cord injury patients receiving rehabilitation therapy. Paraplegia 34, 82-90.
136. Goodin, D.S. (2014). Glucocorticoid treatment of multiple sclerosis. Handb Clin. Neurol. 122, 455-464.
137. Najmi Varzaneh, F., Najmi Varzaneh, F., Azimi, A.R., Rezaei, N., and Sahraian, M.A. (2014). Efficacy of combination therapy with erythropoietin and methylprednisolone in clinical recovery of severe relapse in multiple sclerosis. Acta Neurol. Belg. Epub ahead of print.
138. Gonzalez, R., Hickey, M.J., Espinosa, J.M., Nistor, G., Lane, T.E., and Keirstead, H.S. (2007). Therapeutic neutralization of CXCL 10 decreases secondary degeneration and functional deficit after spinal cord injury in mice. Regen. Med. 2, 771-783.
139. Arnold, S.A., and Hagg, T. (2011). Anti-inflammatory treatments during the chronic phase of spinal cord injury improve locomotor function in adult mice. J. Neurotrauma 28, 1995-2002.
140. Trepanier, P., and Bazin, R. (2012). Intravenous immunoglobulin (IVIg) inhibits CD8 cytotoxic T-cell activation. Blood 120, 2769-2770.
141. Aubin, E., Lemieux, R., and Bazin, R. (2010). Indirect inhibition of in vivo and in vitro T-cell responses by intravenous immunoglobulins due to impaired antigen presentation. Blood 115, 1727-1734.
142. Nguyen, D.H., Cho, N., Satkunendrarajah, K., Austin, J.W., Wang, J., and Fehlings, M.G. (2012). Immunoglobulin G (IgG) attenuates neuroinflammation and improves neurobehavioral recovery after cervical spinal cord injury. J. Neuroinflammation 9.
143. Boster, A., Ankeny, D.P., and Racke, M.K. (2010). The potential role of B cell-targeted therapies in multiple sclerosis. Drugs 70, 2343-2356.
144. Gredler, V., Mader, S., Schanda, K., Hegen, H., Di Pauli, F., Kuenz, B., Deisenhammer, F., Berger, T., Reindl, M., and Lutterotti, A. (2013). Clinical and immunological follow-up of B-cell depleting therapy in CNS demyelinating diseases. J. Neurol. Sci. 328, 77-82.
145. Schnell, L., Fearn, S., Klassen, H., Schwab, M.E., and Perry, V.H. (1999). Acute inflammatory responses to mechanical lesions in the CNS: differences between brain and spinal cord. Eur. J. Neurosci. 11, 3648-3658.
146. Hayes, K.C., Hull, T.C., Delaney, G.A., Potter, P.J., Sequeira, K.A.J., Campbell, K., and Popovich, P.G. (2002). Elevated serum titers of proinflammatory cytokines and CNS autoantibodies in patients with chronic spinal cord injury. J. Neurotrauma 19, 753-761.
147. Dalpke, A.H., Schäfer, M.K., Frey, M., Zimmermann, S., Tebbe, J., Weihe, E. and Heeg, K. (2002). Immunostimulatory CpG-DNA activates murine microglia. J. Immunol. 168, 4854-4863.
148. Hjorth, E., and Freund-Levi, Y. (2012). Immunomodulation of mi-croglia by docosahexaenoic acid and eicosapentaenoic acid. Curr. Opin. Clin. Nutr. Metab. Care 15, 134-143.
149. Tambuyzer, B.R., Ponsaerts, P., and Nouwen, E.J. (2009). Microglia: gatekeepers of central nervous system immunology. J. Leukoc. Biol. 85, 352-370.
150. Profyris, C., Cheema, S.S., Zang, D., Azari, M.F., Boyle, K., and Petratos, S. (2004). Degenerative and regenerative mechanisms governing spinal cord injury. Neurobiol. Dis. 15, 415-436.
151. Polazzi, E., and Monti, B. (2010). Microglia and neuroprotection: From in vitro studies to therapeutic applications. Prog. Neurobiol. 92, 293-315.
152. Choi, K., Kim, M., Ryu, J., and Choi, C. (2007). Ginsenosides compound K and Rh(2) inhibit tumor necrosis factor-alpha-induced activation of the NF-kappaB and JNK pathways in human astroglial cells. Neurosci. Lett. 421, 37-41.
153. Silver, J., and Miller, J.H. (2004). Regeneration beyond the glial scar. Nat. Rev. Neurosci. 5, 146-156.
154. Aloisi, F., Ria, F., Penna, G., and Adorini, L. (1998). Microglia are more efficient than astrocytes in antigen processing and in Th1 but not Th2 cell activation. J. Immunol. 160, 4671-4680.
155. Hall, J.C., Priestley, J.V., Perry, V.H., and Michael-Titus, A.T. (2012). Docosahexaenoic acid, but not eicosapentaenoic acid, reduces the early inflammatory response following compression spinal cord injury in the rat. J. Neurochem. 121, 738-750.
156. McTigue, D.M., Tripathi, R., Wei, P., and Lash, A.T. (2007). The PPAR gamma agonist Pioglitazone improves anatomical and locomo-tor recovery after rodent spinal cord injury. Exp Neurol 205, 396-406.
157. Bracken, M.B., Shepard, M.J., Holford, T.R., Leo-Summers, L., Aldrich, E.F., Fazl, M., Fehlings, M., Herr, D.L., Hitchon, P.W., Marshall, L.F., Nockels, R.P., Pascale, V., Perot, P.L., Jr., Piepmeier, J., Sonntag, V.K., Wagner, F., Wilberger, J.E., Winn, H.R., and Young, W. (1997). Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study. JAMA 277, 1597-1604.
158. Beck, K.D., Nguyen, H.X., Galvan, M.D., Salazar, D.L., Woodruff, T.M., and Anderson, A.J. (2010). Quantitative analysis of cellular inflammation after traumatic spinal cord injury: evidence for a multiphasic inflammatory response in the acute to chronic environment. Brain 133, 433-447.
159. Bao, F., Chen, Y., Dekaban, G.A., and Weaver, L.C. (2004). Early anti-inflammatory treatment reduces lipid peroxidation and protein nitration after spinal cord injury in rats. J. Neurochem. 88, 1335-1344.
160. Yang, L., Blumbergs, P.C., Jones, N.R., Manavis, J., Sarvestani, G.T. and Ghabriel, M.N. (2004). Early expression and cellular localization of proinflammatory cytokines interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha in human traumatic spinal cord injury. Spine 29, 966-971.
161. Fujiki, M., Zhang, Z., Guth, L., and Steward, O. (1996). Genetic influences on cellular reactions to spinal cord injury: activation of macrophages/microglia and astrocytes is delayed in mice carrying a mutation (WldS) that causes delayed Wallerian degeneration. J. Comp. Neurol. 371, 469-484.
162. Popovich, P.G., Wei, P. and Stokes, B.T. (1997). Cellular inflammatory response after spinal cord injury in Sprague-Dawley and Lewis rats. J. Comp. Neurol. 377, 443-464.
163. Vaughn, C.N., Iafrate, J.L., Henley, J.B., Stevenson, E.K., Shlifer, I.G., and Jones, T.B. (2013). Cellular neuroinflammation in a lateral forceps compression model of spinal cord injury. Anat. Rec. 296, 1229-1246.
164. Wu, D., Miyamoto, O., Shibuya, S., Mori, S., Norimatsu, H., Janjua, N.A., and Itano, T. (2005). Co-expression of radial glial marker in macrophages/microglia in rat spinal cord contusion injury model. Brain Res. 1051, 183-188.
165. Schmitt, A.B., Buss, A., Breuer, S., Brook, G.A., Pech, K., Martin, D., Schoenen, J., Noth, J., Love, S., Schroder, J.M., Kreutzberg, G.W., and Nacimiento, W. (2000). Major histocompatibility complex class II expression by activated microglia caudal to lesions of descending tracts in the human spinal cord is not associated with a T cell response. Acta Neuropathol. 100, 528-536.
166. Puckett, W.R., Hiester, E.D., Norenberg, M.D., Marcillo, A.E. and Bunge, R.P. (1997). The astroglial response to Wallerian degeneration after spinal cord injury in humans. Exp. Neurol. 148, 424-432.
167. Chang, H.T. (2007). Subacute human spinal cord contusion: few lymphocytes and many macrophages. Spinal Cord 45, 174-182.
168. Nesic, O., Lee, J., Johnson, K.M., Ye, Z., Xu, G.Y., Unabia, G.C., Wood, T.G., McAdoo, D.J., Westlund, K.N., Hulsebosch, C.E. and Perez-Polo, J.R. (2005). Transcriptional profiling of spinal cord injury-induced central neuropathic pain. J. Neurochem. 95, 998-1014.